Breaking Finance News

RBC Capital announced Incyte (NASDAQ:INCY), bumping up its stock price target to $136.00 today

In a report released on 9/15/2017 RBC Capital increased the stock price target of Incyte (NASDAQ:INCY) to $136.00 reporting a possible upside of 0.14%.

Yesterday Incyte (NASDAQ:INCY) traded -0.27% lower at $119.78. The company’s 50-day moving average is $127.79 and its 200-day moving average is $130.32. The last closing price is down -8.35% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 841,290 shares of the stock were exchanged, down from an average trading volume of 1,362,460

See Chart Below


Incyte has a 52 week low of $79.75 and a 52 week high of $153.15 The company’s market cap is currently $0.

In addition to RBC Capital reporting its target price, a total of 14 brokers have issued a report on the stock. The consensus target price is $91.36 with 7 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Incyte (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.